Part B Drug Rebate Ideas Not Drawing CMS Attention, Despite OIG Prodding
This article was originally published in The Pink Sheet Daily
Executive Summary
The HHS Office of Inspector General finds Medicare Part B could have saved $3.1 billion on 60 of the costliest drugs by applying Medicaid-level rebates, which the office says “warrants further deliberation.” But noting Part B drug rebates are not actively under consideration by the administration or Congress, CMS says it will not devote resources to examining the issue.
You may also be interested in...
Rituxan Could Be Top Source Of Price Inflation Rebates In Medicare Part B
HHS Office of Inspector General estimates $1.4bn to $1.8bn could have been saved in Medicare Part B in 2015 if manufacturers provided rebates when drug prices increased faster than inflation.
Mandated Rebates For Top Part B Drugs Could Save $2 Bil. Per Year – HHS OIG
Mandated Medicaid-level rebates for the 20 most expensive drugs covered under Medicare Part B could have saved $1.9 billion to $2.4 billion in total drug costs in 2010, the HHS Office of Inspector General estimates in a recent analysis.
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.